Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Staging of non-small-cell lung cancer by whole-body fluorine-18 deoxyglucose positron emission tomography


Positron emission tomography (PET) using fluorine-18 deoxyglucose (FDG), showing increased FDG uptake and retention in malignant cells, has been proven useful to differentiate malignant from benign tissue. We undertook a prospective study in 61 patients to compare the accuracy of whole-body FDG PET and conventional imaging (CI) methods for the staging of nonsmall-cell lung cancer (NSCLC). CI included chest and abdomen computed tomographic scanning and bone scintigraphy. When CI or PET study suggested metastatic disease, confirmation was obtained by biopsy or clinical or radiological follow-up. As compared to CI, PET correctly changed the N stage in 13 patients (21%) and the M stage in six patients (10%). There were three false-positive and no false-negative distant PET findings. Our preliminary results show that whole-body FDG PET can improve the diagnostic accuracy in the staging of NSCLC.

This is a preview of subscription content, log in to check access.


  1. 1.

    Shields TW. The significance of ipsilateral mediastinal lymph node metastasis (N2 disease) in non-small cell carcinoma of the lung.Thorac Cardiovasc Surg 1990; 99: 48–53.

  2. 2.

    Kadvi MA, Dussek JE. Survival and prognosis following resection of primary non small cell bronchogenic carcinoma.Eur J Cardiothorac Surg 1991; 5: 132–136.

  3. 3.

    Hatamaka M. Transport of sugars in tumor cell membranes.Biochem Biophys Acta 1974; 355: 74–104.

  4. 4.

    Flier J, Mueckleer M, Usher P, Lodish H. Elevated levels of glucose transport and transporter messenger RNA are induced byras andsarc oncogens.Science 1987; 235: 1492–1495.

  5. 5.

    Tisi G, Friedman P, Peters R, Pearson G, Carr D, Lee R, Selawry O. Clinical staging of primary lung cancer.Am Rev Respir Dis 1983; 127: 659–664.

  6. 6.

    Quint L, Glazer G, Orringer M, Francis I, Bookstein F. Mediastinal lymph node detection and sizing at CT and autopsy.AJR 1986; 147: 469–472.

  7. 7.

    McLoud T, Bourgouin P, Greenberg R, Kosiuk J, Templeton P, Shepard J, Moore E, Wain J, Mathisen D, Grillo H. Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling.Radiology 1992; 182: 319–323.

  8. 8.

    Bragg DG. Current applications of imaging procedures in the patient with lung cancer.Int J Radiat Oncol Biol Phys 1991; 21: 847–885.

  9. 9.

    Reinig J, Doppman J, Dwyer A. Adrenal masses differentiated by MR.Radiology 1986; 158: 81–84.

  10. 10.

    Dewan N, Gupta N, Redepenning L, Phallen J, Frick M. Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules.Chest 1993; 104: 997–1002.

  11. 11.

    Wahl R, Quint L, Greenought R, Meyer C, White R, Orringer M. Staging of mediastinal non-small cell lung cancer with FDG PET, CT and fusion images: preliminary prospective evaluation.Radiology 1994; 191: 371–377.

  12. 12.

    Lewis P, Griffin S, Marsden P, Gee T, Nunan T, Malsey M, Dussek T. Whole-body18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer.Lancet 1994; 344: 1265–1266.

Download references

Author information

Correspondence to T. Bury.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Bury, T., Dowlati, A., Paulus, P. et al. Staging of non-small-cell lung cancer by whole-body fluorine-18 deoxyglucose positron emission tomography. Eur J Nucl Med 23, 204–206 (1996).

Download citation

Key words

  • Positron emission tomography
  • Fluorodeoxyglucose
  • Lung neoplasm